EP3512552A4 - Anti-histone therapy in acute kidney injury - Google Patents

Anti-histone therapy in acute kidney injury Download PDF

Info

Publication number
EP3512552A4
EP3512552A4 EP17851497.2A EP17851497A EP3512552A4 EP 3512552 A4 EP3512552 A4 EP 3512552A4 EP 17851497 A EP17851497 A EP 17851497A EP 3512552 A4 EP3512552 A4 EP 3512552A4
Authority
EP
European Patent Office
Prior art keywords
histone
therapy
kidney injury
acute kidney
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17851497.2A
Other languages
German (de)
French (fr)
Other versions
EP3512552A1 (en
Inventor
Daigo NAKAZAWA
Hans-Joachim Anders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/402,585 external-priority patent/US20170114126A1/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of EP3512552A1 publication Critical patent/EP3512552A1/en
Publication of EP3512552A4 publication Critical patent/EP3512552A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP17851497.2A 2016-09-14 2017-09-14 Anti-histone therapy in acute kidney injury Withdrawn EP3512552A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394529P 2016-09-14 2016-09-14
US15/402,585 US20170114126A1 (en) 2014-06-24 2017-01-10 Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PCT/US2017/051485 WO2018053080A1 (en) 2016-09-14 2017-09-14 Anti-histone therapy in acute kidney injury

Publications (2)

Publication Number Publication Date
EP3512552A1 EP3512552A1 (en) 2019-07-24
EP3512552A4 true EP3512552A4 (en) 2020-05-06

Family

ID=61619282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17851497.2A Withdrawn EP3512552A4 (en) 2016-09-14 2017-09-14 Anti-histone therapy in acute kidney injury

Country Status (3)

Country Link
EP (1) EP3512552A4 (en)
CA (1) CA3031540A1 (en)
WO (1) WO2018053080A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225549A1 (en) * 2019-05-06 2020-11-12 The Francis Crick Institute Limited Method for preventing inflammation
CN113122538A (en) * 2021-04-15 2021-07-16 遵义医科大学附属医院 shRNA expressed by targeted knockdown Rip3 gene, recombinant vector and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642822B2 (en) * 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP3160504B1 (en) * 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Extracellular histones cause vascular necrosis in severe glomerulonephritis", 2015, UNIVERSITY MÜNCHEN, article VANKAYALA RAMAIAH ET AL: "Extracellular histones cause vascular necrosis in severe glomerulonephritis", XP055678928, DOI: https://edoc.ub.uni-muenchen.de/18767/ *

Also Published As

Publication number Publication date
CA3031540A1 (en) 2018-03-22
WO2018053080A1 (en) 2018-03-22
EP3512552A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
EP3463464A4 (en) Combination therapy
EP3488001A4 (en) Treating cancer
HK1245287A1 (en) IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
EP3265575A4 (en) Cd20 binding molecules and uses thereof
HK1256283A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
SI3423087T1 (en) Combination therapy against cancer
GB201607629D0 (en) Mutational signatures in cancer
EP3207162A4 (en) Combination therapy for use in cancer therapy
EP3086834A4 (en) Devices and methods for treating acute kidney injury
EP3575319A4 (en) Bifunctional molecule and use thereof
EP3713585A4 (en) Msc-expressed immunomodulators in combination with car-t for cancer therapy
IL263802A (en) Cancer treatment combinations
EP3487522A4 (en) Anti-cd47 combination therapy
HK1258319A1 (en) Cancer therapy
EP3383282A4 (en) Devices and methods for treating acute kidney injury
EP3202909A4 (en) Cancer specific-splicing ribozyme and use thereof
EP3367496A4 (en) Filter unit and filter
EP3266803A4 (en) Polymer and crosslinked body thereof
EP3419959A4 (en) Combination therapy
EP3541931A4 (en) Fractal combination therapy
IL262143A (en) Improvements in cancer treatment
EP3256115A4 (en) Combination cancer therapy
EP3256473A4 (en) Synergistic cancer treatment
EP3102611A4 (en) Humanized beta-amyloid binding molecules and uses thereof
EP3532638A4 (en) Targeting microrna-101-3p in cancer therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200402

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 259/10 20060101ALI20200328BHEP

Ipc: C07C 311/21 20060101ALI20200328BHEP

Ipc: A61K 39/395 20060101AFI20200328BHEP

Ipc: A61P 13/12 20060101ALI20200328BHEP

Ipc: C07K 16/18 20060101ALI20200328BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221014